GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Urologix Inc (OTCPK:ULGX) » Definitions » Interest Coverage

Urologix (Urologix) Interest Coverage : 0 (At Loss) (As of Mar. 2015)


View and export this data going back to 1996. Start your Free Trial

What is Urologix Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Urologix's Operating Income for the three months ended in Mar. 2015 was $-0.15 Mil. Urologix's Interest Expense for the three months ended in Mar. 2015 was $-0.19 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Urologix's Interest Coverage or its related term are showing as below:


ULGX's Interest Coverage is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 18.56
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Urologix Interest Coverage Historical Data

The historical data trend for Urologix's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Urologix Interest Coverage Chart

Urologix Annual Data
Trend Jun05 Jun06 Jun07 Jun08 Jun09 Jun10 Jun11 Jun12 Jun13 Jun14
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only No Debt No Debt - - -

Urologix Quarterly Data
Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Urologix's Interest Coverage

For the Medical Devices subindustry, Urologix's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Urologix's Interest Coverage Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Urologix's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Urologix's Interest Coverage falls into.



Urologix Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Urologix's Interest Coverage for the fiscal year that ended in Jun. 2014 is calculated as

Here, for the fiscal year that ended in Jun. 2014, Urologix's Interest Expense was $-0.69 Mil. Its Operating Income was $-4.00 Mil. And its Long-Term Debt & Capital Lease Obligation was $4.59 Mil.

Urologix did not have earnings to cover the interest expense.

Urologix's Interest Coverage for the quarter that ended in Mar. 2015 is calculated as

Here, for the three months ended in Mar. 2015, Urologix's Interest Expense was $-0.19 Mil. Its Operating Income was $-0.15 Mil. And its Long-Term Debt & Capital Lease Obligation was $3.54 Mil.

Urologix did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Urologix  (OTCPK:ULGX) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Urologix Interest Coverage Related Terms

Thank you for viewing the detailed overview of Urologix's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Urologix (Urologix) Business Description

Traded in Other Exchanges
N/A
Address
14405 21st Avenue North, Suite 110, Minneapolis, MN, USA, 55447
Urologix Inc is a United States-based company engaged in the development, manufacturing, and marketing of minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). The firm markets the Cooled ThermoTherapy (CTC) product line and the Prostiva Radio Frequency (RF) Therapy System (Prostiva). The CTC produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. The Prostiva delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH voiding symptoms. The CTC product line includes the CoolWave and Targis Control Units and the CTC Advance catheter.
Executives
Emery Sidney W Jr director C/O QUALIGEN THERAPEUTICS, INC., 2042 CORTE DEL NOGAL, CARLSBAD CA 92011
Patrick D Spangler director 14405 21ST AVENUE NORTH, MINNEAPOLIS MN 55447
Gregory Fluet director, officer: CEO 14405 21ST AVENUE NORTH, MINNEAPOLIS MN 55447
William M Moore director
Guy C Jackson director C/O EPICEPT CORPORATION, 777 OLD SAW MILL ROAD, TARRYTOWN NY 10591
Daniel J Starks director ONE ST JUDE MEDICAL DRIVE, ST PAUL MN 55117
Claude Tihon officer: Chief Technology Officer
Bobby Ivan Griffin director 1326 SPRING VALLEY RD GOLDEN VALLEY PA 55422
David A Montecalvo officer: VP, Product Dev. & Operations 530 HERMAN O. WEST DRIVE, EXTON PA 19341
Susan Bartlett Foote director 649 SUMMIT AVENUE, ST PAUL MN 55105

Urologix (Urologix) Headlines

From GuruFocus

Urologix Inc. Reports Operating Results (10-K)

By gurufocus 10qk 09-21-2009

Urologix Inc. (ULGX) CEO Stryker Jr Warren buys 5,200 Shares

By GuruFocus Research GuruFocus Editor 02-01-2011

Urologix Inc. (ULGX) CEO Stryker Jr Warren buys 3,100 Shares

By GuruFocus Research GuruFocus Editor 12-07-2009

Urologix Inc. (ULGX) CEO Stryker Jr Warren buys 16,900 Shares

By GuruFocus Research GuruFocus Editor 12-09-2009

Urologix Inc. Reports Operating Results (10-K)

By gurufocus 10qk 09-17-2010